<div id="readability-page-1"><p><span>Phreesia (NYSE:PHR - Get Free Report)</span> was upgraded by Zacks Research from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Monday,Zacks.com reports.</p><ul><li>Phreesia Stock is a Healthcare IT Play </li></ul><p>PHR has been the subject of several other reports. DA Davidson lifted their price objective on shares of Phreesia from $33.00 to $35.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, December 2nd. Piper Sandler lifted their price target on Phreesia from $33.00 to $34.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, September 5th. Citigroup dropped their price objective on Phreesia from $34.00 to $29.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday. Mizuho began coverage on Phreesia in a research note on Wednesday, August 27th. They set an &#34;outperform&#34; rating and a $36.00 target price for the company. Finally, Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Phreesia in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $32.38.</p><p><b>Get Our Latest Stock Analysis on Phreesia</b></p><h2>Phreesia Stock Performance</h2><p>PHR stock opened at $15.46 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The firm has a market cap of $925.91 million, a price-to-earnings ratio of -154.53 and a beta of 0.64. The firm has a 50-day simple moving average of $21.87 and a two-hundred day simple moving average of $25.19. Phreesia has a one year low of $15.41 and a one year high of $32.76. </p><p>Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.36%. Phreesia's revenue was up 12.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.25) earnings per share.  On average, equities analysts forecast that  Phreesia will post -1.1 EPS for the current fiscal year. </p><h2>Insider Activity at Phreesia</h2><p>In other news, insider Evan Roberts sold 1,888 shares of the company's stock in a transaction on Friday, October 17th. The shares were sold at an average price of $22.36, for a total transaction of $42,215.68. Following the completion of the sale, the insider owned 724,949 shares of the company's stock, valued at $16,209,859.64. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, insider David Linetsky sold 2,059 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $22.36, for a total transaction of $46,039.24. Following the completion of the sale, the insider owned 171,829 shares of the company's stock, valued at $3,842,096.44. This trade represents a 1.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,174 shares of company stock worth $603,835 over the last 90 days. Corporate insiders own  5.50% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. purchased a new stake in shares of  Phreesia in the third quarter valued at approximately $32,000.  Asset Management One Co. Ltd. acquired a new position in  Phreesia during the third quarter worth $45,000.  State of Alaska Department of Revenue purchased a new stake in  Phreesia in the 3rd quarter valued at $83,000.  Farther Finance Advisors LLC grew its holdings in  Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock valued at $86,000 after buying an additional 3,000 shares in the last quarter.  Finally, Anchor Investment Management LLC acquired a new stake in shares of  Phreesia in the 3rd quarter worth $118,000. 92.10% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Phreesia Company Profile</h2> (Get Free Report)<p>Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Phreesia</li><li>Using the MarketBeat Stock Split Calculator</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Most active stocks: Dollar volume vs share volume</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>What Are Trending Stocks? Trending Stocks Explained</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBIUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Phreesia Right Now?</h2><p>Before you consider Phreesia, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.</p><p>While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Zacks Research upgraded Phreesia (NYSE:PHR) from a "hold" to a "strong-buy" rating. Other analysts have also given positive ratings, with DA Davidson, Piper Sandler, and Mizuho raising their price targets. Phreesia reported better-than-expected earnings and revenue for the recent quarter. Insider trading activity showed minor decreases in stock ownership. Institutional investors have made significant changes to their positions in the stock. Phreesia provides SaaS-based software and payment platforms for the healthcare industry in the US and Canada.</p>

Phreesia (NYSE:PHR) Upgraded at Zacks Research